Efficacy and safety of Shenfu injection for patients with return of spontaneous circulation after sudden cardiac arrest

Ye, Jiarong; Zhu, Zehao; Liang, Qianrong; Yan, Xiaofeng; Xi, Xiaotu; Zhang, Zhongde

doi:10.1097/md.0000000000012500

Cited by 5 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22] A P value >.1 and I 2 value of <50% were considered to be of no significant heterogeneity, and a fixed-effect model was used. [23,24] Otherwise, use a random-effect model. [25]…”

Section: Methodsmentioning

confidence: 99%

Could platelet-to-lymphocyte ratio be a predictor for contrast-induced nephropathy in patients with acute coronary syndrome?

Jiang¹,

Xie

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: Contrast-induced nephropathy (CIN) is acute renal failure observed after administration of iodinated contrast media during angiographic or other medical procedures. In recent years, many studies have focused on biomarkers that recognize CIN and/or predict its development in advance. One of the many biomarkers studied is the platelet-to-lymphocyte ratio (PLR). We performed a systematic review and meta-analysis to evaluate the correlation between PLR level and CIN. Methods: Relevant studies were searched in PUBMED, EMBASE, and Web of Science until September 15, 2018. Case-control studies reporting admission PLR levels in CIN and non-CIN group in patients with acute coronary syndrome (ACS) were included. The pooled weighted mean difference (WMD) and 95% confidence intervals (95%CI) were calculated to assess the association between PLR level and CIN using a random-effect model. Results: Six relevant studies involving a total of 10452 ACS patients (9720 non-CIN controls and 732 CIN patients) met our inclusion criteria. A meta-analysis of 6 case-control studies showed that PLR levels were significantly higher in CIN group than those in non-CIN group (WMD = 33.343, 95%CI = 18.863 to 47.823, P < .001, I 2 = 88.0%). Conclusion: For patients with ACS after contrast administration, our meta-analysis shows that on-admission PLR levels in CIN group are significantly higher than those of non-CIN group. However, large and matched cohort studies are needed to validate these findings and assess whether there is a real connection or just an association.

show abstract

“…[22] A P value >.1 and I 2 value of <50% were considered to be of no significant heterogeneity, and a fixed-effect model was used. [23,24] Otherwise, use a random-effect model. [25]…”

Section: Methodsmentioning

confidence: 99%

Could platelet-to-lymphocyte ratio be a predictor for contrast-induced nephropathy in patients with acute coronary syndrome?

Jiang¹,

Xie

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…Several protocols describing clinical trials and systematic reviews or meta-analyses have been published in recent months. Anticipated topics for investigation include cardiac arrest, heart failure, coronary heart disease, sepsis, pediatric respiratory infections, and COVID-19 ( 26 - 33 ). SFI is currently listed as a recommended therapy for severe cases of COVID-19 by the China National Health Commission (NHC) ( 34 ).…”

Section: Discussion and Future Directionsmentioning

confidence: 99%

Shenfu injection as treatment for critical illness: a narrative review of clinical trials

Berlin,

Shekhar,

Berg

2024

J Thorac Dis

View full text Add to dashboard Cite

Background and Objective Shenfu injection (SFI) is a traditional herbal medicine derived from components of ginseng and aconite and is commonly used in China to treat a variety of conditions. Shenfu has been suggested to have beneficial effects in various critical illnesses, including heart failure, cardiac arrest, and septic shock. In recent years, there have been a number of studies reporting that SFI improves patient outcomes when used concurrently with other treatments, but its use has not been adopted outside of China. This narrative review explored the results of clinical trials that have tested SFI’s efficacy in various critical illnesses. Methods PubMed was searched for clinical trials, systematic reviews and meta-analyses published between 1990 and July 2022 relating to clinical trials using SFI in various critical illnesses. Systematic reviews and meta-analyses were included to enable inclusion of data from trials originally not published in English. The selected articles were then summarized in the following disease categories: heart failure, cardiac arrest, sepsis, and severe pulmonary disease. Key Content and Findings Clinical trials testing SFI in heart failure, cardiac arrest, sepsis, and pulmonary disease were reviewed. The design, methodology, and key findings of each trial or meta-analysis are summarized and discussed. Key limitations were also highlighted and discussed. Overall, several clinical trials suggest SFI may hold therapeutic potential for the treatment of critical illness, however, additional research is likely still needed. Conclusions Based on the current body of literature, further research—especially multi-center randomized, double-blind trials with detailed reporting of all methods and results according to international guidelines—is needed to evaluate whether SFI is a useful addition to existing treatments for these conditions.

show abstract

“…The ginsenoside scavenges free radicals, inhibiting inflammatory mediators 7 , 8 , suppressing cellular apoptosis 9 . This traditional Chinese medicine has been routinely administered to treat septic shock, acute myocardial dysfunction, and chronic congestive heart failure and to boost postoperative recovery 10 , 11 . On this basis, the hypothesis is that SFI could protect renal function from circulatory insufficiency induced hemorrhage.…”

Section: Introductionmentioning

confidence: 99%

Shen-fu injection alleviates acute renal injury by reducing cytokine levels and modulating apoptosis in a porcine hemorrhagic shock model

Yuan

Zhang

et al. 2021

Acta Cir. Bras.

View full text Add to dashboard Cite

Purpose Shen-fu injection (SFI) was used to intervene in the resuscitation of porcine hemorrhagic shock (HS) model to study its protective effects on acute kidney injury. Methods After 60 min of HS, 28 animals were randomly assigned into four groups. The groups were as follows: hemorrhagic shock group (HS); HS resuscitation with shed-blood group (HSR); HS resuscitation with shed-blood and SFI (1 mL·kg –1 ) group (HSR-SFI); and the sham operation group (Sham). The bloods were analyzed for serum creatinine (sCr), cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL). BAX, Bcl-2, and caspase-3 protein expressions by Western blot analysis and immunohistochemical staining. The renal tissues were removed and pathologic changes were observed. Results Mean aortic pressure (MAP) in HSR-SFI groups were higher than that in HSR groups after shock. At the 6th hour after shock, the urine volume per hour in the HSR-SFI groups was more than that in the HSR groups. The sCr, NGAL, CysC and cytokine levels of HSR-SFI groups were lower. The Bcl-2 expression was increased in the HSR-SFI groups. The BAX and caspase-3 expressions were reduced. The histopathologic score in the HSR-SFI was lower. Conclusions SFI may reduce the risk of acute kidney injury (AKI) following hemorrhagic shock by attenuating systemic inflammatory responses, and regulating the expression of apoptosis-related proteins.

show abstract

Efficacy and safety of Shenfu injection for patients with return of spontaneous circulation after sudden cardiac arrest

Cited by 5 publications

References 24 publications

Could platelet-to-lymphocyte ratio be a predictor for contrast-induced nephropathy in patients with acute coronary syndrome?

Could platelet-to-lymphocyte ratio be a predictor for contrast-induced nephropathy in patients with acute coronary syndrome?

Shenfu injection as treatment for critical illness: a narrative review of clinical trials

Shen-fu injection alleviates acute renal injury by reducing cytokine levels and modulating apoptosis in a porcine hemorrhagic shock model

Contact Info

Product

Resources

About